LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (drug combination treatments). Dataset 1 of 2: Cell count and normalized growth rate inhibition values. - Dataset (ID:20259)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol 1 Concentration | Small Mol 1 Conc Unit | Small Molecule 2 | Small Mol 2 Concentration | Small Mol 2 Conc Unit | Biological Replicate | Technical Replicate | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Alpelisib | 0.1235 | uM | Lapatinib | 10 | uM | 2 | 1 | 1843 | 1901 | 5129 | 0.0209 |
| BT-20 | Alpelisib | 0.1235 | uM | Lapatinib | 5.7735 | uM | 2 | 1 | 1843 | 2644 | 5129 | 0.2766 |
| BT-20 | Dactolisib | 0.0412 | uM | NVP-TAE684 | 0.3704 | uM | 2 | 1 | 1843 | 2633 | 5129 | 0.2730 |
| BT-20 | Alpelisib | 1.1111 | uM | Neratinib | 0.6415 | uM | 2 | 1 | 1843 | 1108 | 5129 | -0.2918 |
| BT-20 | Alpelisib | 0.6415 | uM | Lapatinib | 10 | uM | 2 | 1 | 1843 | 1573 | 5129 | -0.1020 |